Alignment Healthcare, Inc.

Alignment Healthcare, Inc. (ALHC) Market Cap

Alignment Healthcare, Inc. has a market capitalization of $3.18B.

Price: $15.37

0.30 (1.99%)

Market Cap: 3.18B

NASDAQ · time unavailable

CEO: John E. Kao

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2021-03-26

Website: https://www.alignmenthealthcare.com

Alignment Healthcare, Inc. (ALHC) - Company Information

Market Cap: 3.18B|Sector: Healthcare

Company Profile

Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.

Analyst Sentiment

91%
Strong Buy

From 14 Active Polls

1Y Forecast: $24.33

▲ +58.3% Potential Upside

Consensus Target Metrics

Low Bound

$16

Median

$25

High Bound

$30

Average

$24

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$24.33
▲ +58.30% Upside
Low Target
$16.00
4% Risk
Median Target
$25.00
63% Mid
High Target
$30.00
95% Max
Consensus
Buy
14 / 16 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)3,1773,6183,9693,4732,7773,6052,1592,2621,521
Enterprise Value ($M)2,0962,5373,7293,1852,6363,4882,0552,1421,402
Price to Earnings Ratio (P/E)159.3679.24-90.16232.8444.31-98.89-17.36-21.41-15.84
Price/Earnings-to-Growth Ratio (PEG)3.61-46.884.65-3.07-13.65-13.08-1.89
Price to Sales Ratio (P/S)0.752.933.923.502.733.893.083.272.23
Price to Book Ratio (P/B)15.2617.4922.1421.4619.7033.3421.6219.7512.30
Price to Free Cash Flow Ratio (P/FCF)13.4329.83-59.5721.60131.42431.01-119.97133.76128.98
Enterprise Value to Sales (EV/Sales)2.053.683.202.603.762.933.092.06
Enterprise Value to EBITDA (EV/EBITDA)31.56108.70-1522.17203.2888.271554.49-109.57-181.29-119.34
Debt to Equity Ratio-16.281.591.892.042.343.053.301.921.78
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-6.5%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for ALHC. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALIGNMENT HEALTHCARE INC (ALHC) — Investment Overview

🧩 Business Model Overview

Alignment Healthcare operates a home-based care and care-management delivery model designed to serve seniors enrolled in Medicare Advantage plans. The value chain centers on: (1) contracting with payers/plan sponsors to deliver care under value-based arrangements, (2) deploying multidisciplinary care teams in member homes and care settings, and (3) coordinating clinical pathways across chronic conditions and post-acute episodes to reduce avoidable utilization while meeting quality requirements.

This creates a tightly managed operating loop: member identification and risk stratification → personalized care plans → ongoing in-home monitoring and care coordination → performance measurement against quality and utilization benchmarks → incentive economics tied to outcomes and costs.

💰 Revenue Streams & Monetisation Model

Revenue is typically structured around risk-adjusted, recurring economics (often described as per-member-per-month style consideration) combined with incentive components tied to quality, satisfaction, and/or shared savings under payer contracts. The business also benefits from a delivery model that can convert “care intensity” into measurable reductions in avoidable utilization.

Key margin drivers include:

  • Medical cost trend and utilization management: reducing avoidable admissions, emergency utilization, and duplicative services.
  • Care delivery productivity: scaling care team capacity while maintaining outcomes and compliance.
  • Contract quality and performance incentives: the degree to which contracts include measurable quality outcomes and shared-savings mechanics.

🧠 Competitive Advantages & Market Positioning

Alignment’s moat is primarily an integrated delivery ecosystem with operational know-how in risk-bearing care management. Competitors can replicate components (telehealth, care coordination, home visits), but replicating the full system—clinical workflows, member engagement cadence, utilization pathways, and payer performance reporting—requires time, staffing depth, and contracting experience.

  • Integrated ecosystem & execution barriers: a coordinated model that links clinician teams, care plans, and performance measurement in a consistent operating cadence. This raises the practical barriers to entry for new entrants.
  • High switching costs for payer contracting: payers incur measurable transition and performance risks when swapping providers, especially when contracts tie reimbursement to utilization and quality outcomes. Provider “replacement” involves operational onboarding, data/process integration, and performance ramp.
  • Operational learning curve: outcomes improve when care teams build repeatable playbooks for common chronic and post-acute trajectories, strengthening cost and quality discipline over time.

Competitive benchmarking (primary peers):

  • Clover Health: a Medicare Advantage–oriented platform with a heavier emphasis on analytics and plan-level capabilities. Alignment focuses more directly on hands-on, home-based care delivery under payer arrangements.
  • Amedisys: home health and hospice services provider with broad geographic reach. Alignment’s differentiation is its value-based, care-management integration rather than primarily fee-for-service provider economics.
  • Encompass Health: post-acute and rehabilitation provider. Alignment emphasizes upstream chronic care and care coordination to influence utilization patterns earlier in the care continuum.

Net: while peer competition exists across home care, post-acute, and Medicare Advantage enablement, Alignment’s positioning is best understood as a payers-facing, integrated care-management operator rather than a pure-play home health agency or purely a plan-analytics vendor.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand for better chronic disease management and a continued shift toward value-based care. Primary drivers include:

  • Medicare Advantage penetration: as enrollment expands, so does demand for provider partners capable of managing utilization and maintaining quality metrics.
  • Aging demographics and rising chronic conditions: increasing need for coordinated care that reduces avoidable utilization and improves member outcomes.
  • Value-based reimbursement expansion: payers seek partners with operational capability to manage medical cost trend while meeting performance targets.
  • Care model migration to home and hybrid settings: the delivery of care in member homes and coordinated settings remains a scalable approach to reach medically complex populations.
  • Contract breadth and contract durability: multi-year payer relationships can translate into compounding operational scale, improving unit economics when performance is sustained.

⚠ Risk Factors to Monitor

  • Medical cost volatility: risk-bearing economics can be pressured by higher-than-expected utilization, acuity mix changes, or imperfect risk adjustment.
  • Quality and compliance risk: performance outcomes tied to contracts can be affected by documentation, care plan adherence, and patient engagement variability.
  • Regulatory reimbursement changes: changes to Medicare Advantage rules, risk adjustment methodologies, or quality program scoring can alter contract economics.
  • Staffing and operational execution: sustaining clinician capacity, training, and care team retention is critical in home-based models.
  • Payer concentration and contracting dynamics: contract renewals, pricing terms, and incentive design can materially impact revenue trajectory.
  • Competitive pressure: large health systems and vertically integrated payers may expand provider networks, increasing acquisition costs and pressuring contract terms.

📊 Valuation & Market View

The market typically values healthcare services and value-based care platforms through revenue quality and margin durability rather than simple growth alone. Common valuation lenses include:

  • P/S for revenue scale when growth is expected to persist and economics are improving.
  • EV/EBITDA or operating leverage metrics as profitability becomes more visible and medical cost trends stabilize.
  • Unit economics focus: medical cost ratio trend, care management productivity, and the trajectory of incentive earnings.
  • Contract signal: payer relationship quality, renewal cadence, and the balance between fixed economics and performance-linked incentives.

Key drivers that move valuation in this sector tend to be consistent contract performance, improving operating leverage, and demonstrated ability to manage utilization while meeting quality standards.

🔍 Investment Takeaway

Alignment Healthcare presents a long-term investment case built on an integrated, value-based home care delivery ecosystem that can create practical switching costs for payers and an execution-driven barrier to entry. The core thesis depends on sustained performance: controlling medical cost trend, maintaining quality and compliance under contract incentives, and scaling care operations without degrading outcomes.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ALHC.

fool.com2026-06-05

Claude responded: Alignment Healthcare's CEO Sold Shares — But the Real Risk Is Policy, Not InsidersAlignment Healthcare's CEO Sold Shares — But the Real Risk Is Policy, Not Insiders

As a Medicare Advantage provider focused on tech-enabled care, this California-based firm reported a notable insider sale last week.

zacks.com2026-06-05

Boost Your Portfolio Returns With These 4 Top-Performing Liquid Stocks

ALHC, TOST, TTMI and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

globenewswire.com2026-06-03

Alignment Healthcare Named to the Fortune 1000 2026 List for Second Consecutive Year

The company rises 196 spots to No. 791 on the Fortune 1000 2026 list following continued growth and momentum The company rises 196 spots to No. 791 on the Fortune 1000 2026 list following continued growth and momentum

zacks.com2026-06-03

Down 25.5% in 4 Weeks, Here's Why Alignment Healthcare (ALHC) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Alignment Healthcare (ALHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

zacks.com2026-06-02

Here's Why Alignment Healthcare (ALHC) is Poised for a Turnaround After Losing 31.0% in 4 Weeks

Alignment Healthcare (ALHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

globenewswire.com2026-06-02

Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report

Fifth annual report introduces refreshed impact strategy, aligned with long-term, responsible growth Fifth annual report introduces refreshed impact strategy, aligned with long-term, responsible growth

gurufocus.com2026-05-29

Alignment Healthcare Inc (ALHC) Stock Down 3.2% -- Now Undervalued? GF Score: 86/100

On May 29, 2026, Alignment Healthcare Inc (ALHC) shares fell 3.2% to a current price of $15.35. The stock has experienced a volatile performance, with a 52-week

zacks.com2026-05-25

CON or ALHC: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Alignment Healthcare (ALHC). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com2026-05-20

4 Top-Ranked Liquid Stocks to Add to Portfolio for Solid Returns

ALHC, AGX, CIEN and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

globenewswire.com2026-05-18

Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

ORANGE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, Florida, on Tuesday, June 9, at 10:40 a.m.

globenewswire.com2026-05-14

Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality

Pharmacy Quality Alliance award underscores sustained excellence in care delivery, medication adherence and pharmacy excellence for seniors Pharmacy Quality Alliance award underscores sustained excellence in care delivery, medication adherence and pharmacy excellence for seniors

marketbeat.com2026-05-13

Alignment Healthcare Backs Q2 Outlook as Stable Costs, New Markets Lift Margin Hopes

Alignment Healthcare NASDAQ: ALHC executives said the company remains confident in its second-quarter outlook, citing stable medical cost trends, continued visibility into utilization and opportunities to expand margins as it grows outside California.

seekingalpha.com2026-05-13

Alignment Healthcare, Inc. (ALHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Alignment Healthcare, Inc. (ALHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

forbes.com2026-05-12

Alignment Healthcare CEO Adds Chairman Role As Medicare Business Grows

Alignment Healthcare is bolstering its management team, adding the chairman's role to top executive and founder John Kao's duties while promoting several other executives as the company sells more Medicare Advantage plans.

globenewswire.com2026-05-12

Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation

Founder and CEO John Kao Assumes Additional Role as Chairman of the Board Founder and CEO John Kao Assumes Additional Role as Chairman of the Board

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ALHC reported Q1 2026 revenue of $1.235B and EPS of $0.06 (diluted $0.05), alongside net income of $11.4M. On a YoY basis, revenue rose +33.3% (vs. $926.9M in Q1 2025) and net income turned positive from a $-9.1M loss (+$20.5M swing). QoQ, revenue grew +21.9% (vs. $1.0128B in Q4 2025) and net income improved from -$11.0M in Q4 2025 to +$11.4M. Profitability improved sharply: net margin expanded to ~0.92% from ~-1.09% in Q4 2025 and from ~-0.98% in Q1 2025. Operating income also swung to +$15.5M (vs. -$10.3M in Q4 2025), supported by a recovery in EBITDA to $23.3M (vs. -$2.5M in Q4 2025). Over the quarter, operating cash flow was strong at $128.7M and free cash flow was $128.7M (capex $0 reported), contrasting with negative operating cash flow in Q4 2025 (-$50.4M). Balance sheet resilience improved: cash increased to $706M while total equity rose to $207M. Total shareholder return appears modest given the 1Y price change of +8.9% (below 20% momentum threshold) and no dividend/buyback activity reported in the quarter."

Revenue Growth

Good

Revenue +21.9% QoQ (Q4’25 to Q1’26) and +33.3% YoY (Q1’25 to Q1’26), indicating accelerating top-line recovery.

Profitability

Positive

Net income improved from -$11.0M (Q4’25) to +$11.4M (Q1’26); net margin turned to ~0.92%. Margins are expanding vs. both prior quarter and year-ago.

Cash Flow Quality

Positive

Operating cash flow rebounded to $128.7M in Q1’26 from -$50.4M in Q4’25. With $0 reported capex, free cash flow matched operating cash flow.

Leverage & Balance Sheet

Neutral

Equity increased to ~$207M and cash rose to ~$706M; net debt remains strongly negative (net-cash position). Leverage appears manageable, though retained earnings remain deeply negative.

Shareholder Returns

Neutral

1Y price change is +8.9% (no >20% momentum boost). No dividends and no buybacks are shown in Q1’26 cash flow.

Analyst Sentiment & Valuation

Good

Consensus price target ($24.5) versus current price ($21.22) implies ~15.5% upside; target range suggests constructive but not extreme upside.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Alignment Healthcare delivered a strong Q1 with 284,800 members (+31% YoY) and $1.2B revenue (+33% YoY). Profitability improved despite a brief CMS-driven internal workflow disruption: adjusted MBR reached 88.2% (+20 bps), adjusted SG&A ratio fell to 8.7% (-60 bps), and adjusted EBITDA margin rose to 3.1% (+90 bps). Management attributed the single-month blip to incorrect acute vs observation authorization timing, corrected within ~30 days, and emphasized utilization is tracking to expectations post-resolution. The bigger story is operating leverage enabled by automation and AI-enabled workflows: claims auto-adjudication rose from <15% to >60% and contract management/AVA models are scaling. Guidance was raised for 2026 and Q2, with first-half EBITDA expected to accelerate versus last year (~+100 bps margin expansion). Key ongoing risk is cautious “newbie” risk adjustment until CMS paid files/final suites provide upside confirmation.

AI IconGrowth Catalysts

  • 31% YoY membership growth to 284,800 supported 33% YoY revenue growth to $1.2B
  • Improved clinical execution supporting adjusted MBR of 88.2% (+20 bps YoY)
  • Member retention outperformance through open enrollment period supporting raised full-year membership guidance
  • Scaling infrastructure investments enabling SG&A leverage (adjusted SG&A ratio 8.7%, -60 bps YoY)

Business Development

  • CMS (Medicare Advantage policy) observation/utilization management rule change affecting inpatient admissions timing and authorization workflows
  • Administration policy signals referenced: Wiser pilot (Medicare overspending control) and overutilization action on skin substitute products in fee-for-service
  • GLP-1 voluntary pilot participation discussed (no partner named in transcript)

AI IconFinancial Highlights

  • Revenue: $1.2B, +33% YoY (Q1 guidance met/exceeded implied performance)
  • Adjusted gross profit: $146M with adjusted MBR 88.2%, improved ~20 bps YoY
  • Adjusted SG&A: $108M; ratio improved to 8.7% from 9.4% (about 60 bps YoY improvement); outperformed guidance midpoint by ~50 bps while still investing
  • Adjusted EBITDA: $38M; margin 3.1% (+90 bps YoY), exceeding high end of guidance range
  • Inpatient admissions per 1,000: “high 150s” in Q1; temporary internal workflow disruption from observation vs acute authorization caused “a couple million dollars” impact and higher timing by a couple of days
  • Part D running modestly favorable for first 3 months; remainder of medical costs in line with supplemental benefit costs

AI IconCapital Funding

  • Cash/cash equivalents/short-term investments: $726M at end of Q1
  • Funded leverage ratio improved to 2.6x trailing-12 EBITDA
  • No buyback authorization/amount or new debt issuance was stated in the provided excerpt

AI IconStrategy & Ops

  • Claims automation: claims auto-adjudication rate increased from <15% (12 months ago) to >60% year-to-date; expected to rise further throughout 2026
  • Contract management infrastructure: deploying AI-based contract management solutions for a more dynamic platform
  • AVA AI risk stratification model: advancing for greater precision in clinical engagement
  • Provider data management scalability investment to support growth beyond current operational reach
  • Operational discipline: root-cause found and corrected within ~30 days after early-January anomalies; utilization tracked to expectations by February/March
  • Observation determination process impacted by CMS rule change; resolved by end of February

AI IconMarket Outlook

  • Full-year 2026 guidance (raised): membership 294,000–299,000; revenue $5.16B–$5.21B (midpoint ~ $5.2B, +31% YoY)
  • Full-year 2026 profitability guidance: adjusted gross profit $620M–$650M; adjusted EBITDA $138M–$163M (raised low end of each by $5M)
  • Q2 2026 guidance: membership 288,000–290,000; revenue $1.30B–$1.32B; adjusted gross profit $167M–$177M; adjusted EBITDA $50M–$60M
  • First-half emphasis: midpoint implies ~60% of full-year EBITDA generated in first half of 2026 vs ~55% in first half of 2025 (excluding new member final suites); nearly +100 bps first-half adjusted EBITDA margin expansion YoY
  • Assumptions: inpatient admissions per 1,000 expected higher YoY due to mix; no assumption for final suite pickup from new members

AI IconRisks & Headwinds

  • Temporary internal workflow issue from CMS rule change: paid authorizations at full acute rates instead of observation rates; impacted January numbers (“couple million dollars”) and admission timing by a couple of days (corrected by end of February)
  • “Newbies” risk uncertainty: risk adjustment booked to paid MMR (opportunity for upside later via final suites, but cautious stance until CMS paid files arrive)
  • CMS risk model/risk adjustment methodology uncertainty: management expects changes/normalization over 2027–2029 timeframe (no specifics in transcript)
  • RADV audit methodology litigation over extrapolation methodology (2020 audits differ because extrapolation methodology is not included in 2020; litigation could return later)
  • Conservatism/claims reserving dynamics: DCP days increased in Q1/this quarter (noted Part D/CMS components can make interpretation more complex), requiring continued reserve oversight

Q&A: Analyst Interest

  • Topic: Observation vs acute authorization workflow disruption—cause, scope, resolution timing. Management’s response: It was an internal workflow problem after a CMS rule change requiring more timely authorizations; they paid full acute when observation rates were appropriate, impacting January by a couple million dollars, then found root cause in January and corrected by February, with utilization tracking as expected by April.
  • Topic: Q2 MBR and margin trajectory assumptions vs Q1—what drives YoY improvement. Management’s response: Q2 is typically seasonally better with natural MBR decline. For the first half, they expect improvements across MBR, SG&A, and EBITDA on an apples-to-apples pre-suite basis, targeting ~40 bps MBR improvement, ~40 bps SG&A improvement, and ~90–100 bps EBITDA improvement through the first half.
  • Topic: CMS risk adjustment on “newbies” and future risk model—how they protect downside and capture upside. Management’s response: They book revenue to paid MMR for new members (cautious until CMS paid files are received), creating upside later when final suites arrive. They also indicated CMS’s direction is to avoid “gamified” coding advantages and expect normalization via preliminary/advanced notices and potential implementation around 2027–2029.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ALHC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ALHC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ALHC)

© 2026 Stock Market Info — Alignment Healthcare, Inc. (ALHC) Financial Profile